Experience with aluminum perrhenate targets for reactor production of high specific activity Re-186

Applied Radiation and Isotopes

Volumn 48, Issue 1, 1997, Pages 1-4

  Ehrhardt, G J ^a   Blumer, M E ^a   Su, F M ^b   Vanderheyden, J L ^b   Fritzberg, A R ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b Poniard Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCIDENT PREVENTION; ALUMINUM COMPOUNDS; ION BOMBARDMENT; IRRADIATION; NEUTRONS; NUCLEAR REACTORS; PRODUCTION; RADIOACTIVITY; TARGETS;

ALUMINUM PERRHENATE; NEUTRON BOMBARDMENT; RADIATION SAFETY; SPECIFIC ACTIVITY;

RHENIUM;

ALUMINUM SALT; RADIOISOTOPE; RHENIUM 186;

ARTICLE; CONTROLLED STUDY; PRIORITY JOURNAL;

EID: 0031023437     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8043(96)00124-8     Document Type: Article

References (10)

1. Breitz H., Weiden P., Vanderheyden J.-L., Appelbaum J., Bjorn M., Fer M., Wolf S., Ratliff B., Seiler C., Foise D., Fisher D., Schroff R., Fritzberg A. and Abrams P. (1992) Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J. Nucl. Med. 33, 1099-1112.
2. Coursey B. M., Cessna J., Garcia-Torano E., Golas D. B., Malonda A. G., Gray D. H., Hoppes D. D., Los Arcos A. M., Martin-Casallo M. T., Schima F. J. and Unterweger M. P. (1991) The standardization and decay scheme of rhenium-186. Appl. Radiat. Isot. 42, 9, 865-869.
3. Fritzberg A., Vanderheyden J.-L., Morgan A., Schroff R. and Abrams P. (1990) Rhenium-186/-188 labeled antibodies for radioimmunotherapy. In Technetium and Rhenium in Chemistry and Nuclear Medicine 3 (Nicolini M., Bandoli G. and Mazzi U., Eds), pp. 615-622. Cortina International, Verona.
4. Lederer C. M. and Shirley V. S. (Eds) (1978) Table of the Isotopes, 7th Edn, p. 1178. Wiley, New York.
5. Lide D. R. (Ed.) (1991) CRC Handbook of Chemistry and Physics, 71st Edn, pp. 4-96.
6. Maxon III H. R., Schroder L. E., Hertzberg V. S., Thomas S. R., Englaro E. E., Samaratunga R., Smith H., Moulton J. S., Williams C. C., Ehrhardt G. J. and Schneider H. J. (1991) Re-186 (Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J. Nucl. Med. 32 (10), 1877.
7. Maxon III H. R., Thomas S. R., Hertzberg V. S., Schroder L. E., Englaro E. E., Samaratunga R., Scher H. I., Moulton J. S., Deutsch E. A., Deutsch K. F., Williams C. C. and Ehrhardt G. J. (1992) Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin. Nucl. Med. XXII (1), 33-40.
8. Spencer R. P., Seevers Jr R. H. and Friedman A. M. (1987) Radionuclides in Therapy, pp. 84-89. CRC Press, Boca Raton, Fla.
9. 2GABA antibody radio-labeling for high dose radioimmunotherapy studies. Technetium and Rhenium in Chemistry and Nuclear Medicine 4 (Nicolini M., Bandoli G. and Mazzi U., Eds), pp. 511-517. SGEditoriali, Padua, Italy.
10. Varfolomeev M. B., Yakovlena N. B. and Plyushchev V. E. (1969) Aluminium and gallium perrhenate heptahydrates. Russ. J. Inorg. Chem. 14, 1, 35-35.